Q3 Results

Accenture, an IT services and consulting company with a significant workforce in India, on Thursday reported a net income of USD 2.39 billion in the March-May quarter, up from USD 2.24 billion in the year-ago period. Accenture follows a September-August financial year, making March-May the third quarter of FY26. The Dublin, Ireland-headquartered firm reported a revenue of USD 18.7 billion in the quarter ended May. It had reported a revenue of USD 17.7 billion in the same period of the previous fiscal year. The firm recorded new bookings totalling USD 19.3 billion during the quarter under review, as compared to USD 19.7 billion in Q3 FY25. "Demand for large-scale reinvention remains strong -- 104 quarterly client bookings of USD 100 million or more year-to-date, up 13 per cent -- and we are seeing more large-scale AI transformation programmes while executing our strategy to capture new areas of growth," Accenture Chair and CEO Julie Sweet said.

In a clarification to the stock exchanges on surge in trading volume, Black Box said there was no undisclosed / price sensitive information or any impending announcement / corporate action.

Trent reported a net profit of ₹413.1 crore in Q4FY26, up 32.57 per cent from ₹311.6 crore in the year-ago period

Pernod Ricard reported strong growth in India mainly driven by premiumisation thus giving a positive outlook for other liquor companies operating in the country.

In the past three trading days, the stock price of iron & steel products company has surged 41 per cent.

As India moves toward reducing dependence on imported crude oil, Ola Electric said it will continue to focus on advancing battery technology and accelerating EV adoption.

Cipla declined 2% to ₹1,195.15, also its lowest level since December 2023 on the BSE in Wednesday's intra-day trade.

A combined 60.9 million equity shares representing 36.5 per cent of total equity of NOCIL changed hands on the NSE and BSE till 11:25 AM on Tuesday.

In the December quarter, Shree Ram Twistex posted a net profit of ₹3.7 crore, as compared to ₹2.2 crore year-on-year (Y-o-Y), up 70 per cent.

In the ferrous space, analysts at ICICI Securities don't foresee any major impact due to ongoing geopolitical tensions as exports share of total steel production is pegged at <6 per cent.

Infosys's stock price has corrected 25 per cent thus far in the calendar year 2026, as against 11.4 per cent fall in Nifty 50, on likely threat to revenue growth.

Ipca Labs hit a 52-week high of ₹1,624 on the BSE in Tuesday's intra-day trade amid heavy volumes and was seen inching towards its record high of ₹1,757.55 touched on January 3, 2025.

Analysts believe the recent stock market correction due to the ongoing conflict between Iran and Israel-US and resultant dislocations in stock prices, presents an opportunity to add 'better' stocks.

Till 12:57 PM on Monday, a combined 19.96 million shares representing 1.23 per cent of Bandhan Bank's total equity changed hands on the NSE (19.15 million shares) and BSE (0.81 million shares).

A combined 27.84 million equity shares representing 8.75 per cent of total equity of the Zydus Wellness changed hands on the NSE and BSE till 01:37 PM on Friday.

The average trading volumes on the ATGL counter jumped over 20-fold with a combined 16.44 million equity shares changing hands on the NSE and BSE till 01:16 PM.

Sun Pharma is transitioning its US business from low-margin generics to high-value specialty and innovative therapies.

Thus far in the calendar year 2026, TCS's market price plunged 23 per cent, as against 7.4 per cent decline in Nifty 50, data shows. The NIfty IT index lost over 1 per cent in trade on Tuesday.

In the past four trading days, the stock price of Natco Pharma has surged 10 per cent after the company announced the launch of Pomalidomide Capsules (generic of Pomalyst) in the US market.

Emcure Pharmaceuticals stock was quoting close to its 52-week high of ₹1,585.50 on Monday, and has surged up to 62% in the last one year.